OBJECTIVES: To assess the cost-effectiveness of the 6-month Team Education and Adherence Monitoring (TEAM) intervention for black patients with hypertension in community pharmacies using prospectively collected cost data. DESIGN:Cost-effectiveness analysis of a cluster-randomized trial. SETTING:Twenty-eight chain pharmacies in 5 Wisconsin cities from December 2006 to February 2009. PARTICIPANTS: Five hundred seventy-six black patients with uncontrolled hypertension. INTERVENTION: Pharmacists and pharmacy technicians using novel tools for improving adherence and feedback to patients and physicians as compared to information-only control group. MAIN OUTCOME MEASURES: Incremental cost analysis of variable costs from the pharmacy perspective captured prospectively at the participant level. Outcomes (effect measures) were 6-month refill adherence, changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP), and proportion of patients achieving blood pressure (BP) control. RESULTS:Mean cost of intervention personnel time and tools was $104.8 ± $45.2. Incremental variable costs per millimeter of mercury decrease in SBP and DBP were $22.2 ± 16.3 and $66.0 ± 228.4, respectively. The cost of helping 1 more person achieve the BP goal (<140/90 mm Hg) was $665.2 ± 265.2; the cost of helping 1 more person achieve good refill adherence was $463.3 ± 110.7. Prescription drug costs were higher for the TEAM group ($392.8 [SD = 396.3] versus $307.0 [SD = 295.2]; P = 0.02). The startup cost for pharmacy furniture, equipment, and privacy screen was $168 per pharmacy. CONCLUSION: Our randomized, practice-based intervention demonstrates that community pharmacists can implement a cost-effective intervention to improve hypertension control in blacks. This approach imposes a nominal expense at the pharmacy level that can be integrated into the ongoing pharmacist-patient relationship, and can enhance clinical and behavioral outcomes.
RCT Entities:
OBJECTIVES: To assess the cost-effectiveness of the 6-month Team Education and Adherence Monitoring (TEAM) intervention for black patients with hypertension in community pharmacies using prospectively collected cost data. DESIGN: Cost-effectiveness analysis of a cluster-randomized trial. SETTING: Twenty-eight chain pharmacies in 5 Wisconsin cities from December 2006 to February 2009. PARTICIPANTS: Five hundred seventy-six black patients with uncontrolled hypertension. INTERVENTION: Pharmacists and pharmacy technicians using novel tools for improving adherence and feedback to patients and physicians as compared to information-only control group. MAIN OUTCOME MEASURES: Incremental cost analysis of variable costs from the pharmacy perspective captured prospectively at the participant level. Outcomes (effect measures) were 6-month refill adherence, changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP), and proportion of patients achieving blood pressure (BP) control. RESULTS: Mean cost of intervention personnel time and tools was $104.8 ± $45.2. Incremental variable costs per millimeter of mercury decrease in SBP and DBP were $22.2 ± 16.3 and $66.0 ± 228.4, respectively. The cost of helping 1 more person achieve the BP goal (<140/90 mm Hg) was $665.2 ± 265.2; the cost of helping 1 more person achieve good refill adherence was $463.3 ± 110.7. Prescription drug costs were higher for the TEAM group ($392.8 [SD = 396.3] versus $307.0 [SD = 295.2]; P = 0.02). The startup cost for pharmacy furniture, equipment, and privacy screen was $168 per pharmacy. CONCLUSION: Our randomized, practice-based intervention demonstrates that community pharmacists can implement a cost-effective intervention to improve hypertension control in blacks. This approach imposes a nominal expense at the pharmacy level that can be integrated into the ongoing pharmacist-patient relationship, and can enhance clinical and behavioral outcomes.
Authors: Hayden B Bosworth; Tara Dudley; Maren K Olsen; Corrine I Voils; Benjamin Powers; Mary K Goldstein; Eugene Z Oddone Journal: Am J Med Date: 2006-01 Impact factor: 4.965
Authors: Alice Dragomir; Robert Côté; Louise Roy; Lucie Blais; Lyne Lalonde; Anick Bérard; Sylvie Perreault Journal: Med Care Date: 2010-05 Impact factor: 2.983
Authors: Beverly B Green; Andrea J Cook; James D Ralston; Paul A Fishman; Sheryl L Catz; James Carlson; David Carrell; Lynda Tyll; Eric B Larson; Robert S Thompson Journal: JAMA Date: 2008-06-25 Impact factor: 56.272
Authors: Fadia T Shaya; Dongyi Du; Confidence M Gbarayor; Feride Frech-Tamas; Helen Lau; Matthew R Weir Journal: J Natl Med Assoc Date: 2009-01 Impact factor: 1.798
Authors: Verughese Jacob; Jeffrey A Reynolds; Sajal K Chattopadhyay; David P Hopkins; Nicole L Therrien; Christopher D Jones; Jeffrey M Durthaler; Kimberly J Rask; Alison E Cuellar; John M Clymer; Thomas E Kottke Journal: Am J Prev Med Date: 2021-12-04 Impact factor: 5.043
Authors: Liz Steed; Ratna Sohanpal; Adam Todd; Vichithranie W Madurasinghe; Carol Rivas; Elizabeth A Edwards; Carolyn D Summerbell; Stephanie Jc Taylor; R T Walton Journal: Cochrane Database Syst Rev Date: 2019-12-06
Authors: Imama A Naqvi; Ying Kuen Cheung; Kevin Strobino; Hanlin Li; Sarah E Tom; Zehra Husaini; Olajide A Williams; Randolph S Marshall; Adriana Arcia; Ian M Kronish; Mitchell S V Elkind Journal: Pilot Feasibility Stud Date: 2022-04-11
Authors: Suzete Costa; José Guerreiro; Inês Teixeira; Dennis K Helling; João Pereira; Céu Mateus Journal: Front Pharmacol Date: 2022-09-08 Impact factor: 5.988